Volasertib is a Polo-like kinase inhibitor, which is a valid target in GBM, but it doesn't have full FDA approval yet, so it would likely be very difficult to get this outside of a clinical trial.
Another drug that downregulates Polo-like kinase is disulfiram:
Yes, there was a phase 1 dose-finding trial in GBM just published. http://www.ncbi.nlm.nih.gov/pubmed/26966095
However, no copper was added in these patients. As part of the same trial, copper + disulfiram is now being combined but no results have been published for that arm of the trial yet.
Volasertib is a Polo-like kinase inhibitor, which is a valid target in GBM, but it doesn't have full FDA approval yet, so it would likely be very difficult to get this outside of a clinical trial.
ReplyDeleteAnother drug that downregulates Polo-like kinase is disulfiram:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717961/
Stephen do you know is disulfiram inhibits plk-1 ? As opposed to other plk family members ?
ReplyDelete" Consistent with its role in suppressing GBM growth, DSF inhibited the expression of PLK1 in GBM cells"
ReplyDeleteHas there been any human trails using dsf?
ReplyDeleteYes, there was a phase 1 dose-finding trial in GBM just published.
ReplyDeletehttp://www.ncbi.nlm.nih.gov/pubmed/26966095
However, no copper was added in these patients. As part of the same trial, copper + disulfiram is now being combined but no results have been published for that arm of the trial yet.